Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
TEMPLE CITY, Calif., April 23, 2018 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2018 financial results after the market closes on Monday, May 7, 2018. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 7588519. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 7588519 through May 14, 2018.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
